Clovis Oncology (CLVS) Earning Somewhat Positive Media Coverage, Analysis Shows
Press coverage about Clovis Oncology (NASDAQ:CLVS) has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Clovis Oncology earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.2290014285155 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Share Activity Lifted for Clovis Oncology Inc (CLVS) in Session – Evergreen Caller (evergreencaller.com)
- Clovis Oncology, Inc. (CLVS) Internals Are Exhibiting Conflicting Signs – StockNewsGazette (stocknewsgazette.com)
- Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : August 17, 2017 (finance.yahoo.com)
- Clovis Oncology, Inc. (CLVS) Now Covered by Analysts at Evercore ISI (americanbankingnews.com)
- 15.5% Return Seen to Date on SmarTrend Clovis Oncology Call (CLVS) (mysmartrend.com)
A number of brokerages have recently issued reports on CLVS. Cann began coverage on Clovis Oncology in a report on Thursday, June 22nd. They set a “market perform” rating for the company. Evercore ISI initiated coverage on Clovis Oncology in a research note on Wednesday. They issued an “in-line” rating and a $73.00 price target for the company. BidaskClub upgraded Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Zacks Investment Research cut Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, Vetr upgraded Clovis Oncology from a “hold” rating to a “buy” rating and set a $87.50 price target for the company in a research note on Wednesday, July 19th. Nine equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $81.91.
Shares of Clovis Oncology (NASDAQ:CLVS) opened at 69.87 on Friday. Clovis Oncology has a 1-year low of $16.61 and a 1-year high of $99.45. The firm’s 50-day moving average price is $84.61 and its 200 day moving average price is $67.36. The company’s market capitalization is $3.42 billion.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.27) by $0.02. The business had revenue of $14.62 million for the quarter, compared to analysts’ expectations of $13.07 million. During the same period last year, the firm posted ($2.07) earnings per share. Clovis Oncology’s revenue for the quarter was down 32.5% on a year-over-year basis. Equities analysts predict that Clovis Oncology will post ($7.53) EPS for the current fiscal year.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $61.82, for a total value of $185,460.00. Following the completion of the transaction, the insider now directly owns 200,583 shares of the company’s stock, valued at approximately $12,400,041.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director James C. Blair sold 18,450 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the completion of the transaction, the director now directly owns 2,185 shares of the company’s stock, valued at $171,762.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,450 shares of company stock valued at $2,120,645. Insiders own 17.40% of the company’s stock.
WARNING: “Clovis Oncology (CLVS) Earning Somewhat Positive Media Coverage, Analysis Shows” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/18/clovis-oncology-clvs-earning-somewhat-positive-media-coverage-analysis-shows.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.